Quest Diagnostics Incorporated provided consolidated earnings guidance for the fiscal year 2022. For the year, the company expects net revenues to be in the range of $9.2 billion to $9.5 billion; and reported diluted EPS to be in the range of $7.88 to $8.38.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
137.6 USD | +0.62% | +8.32% | -0.24% |
Apr. 24 | Jefferies Adjusts Price Target on Quest Diagnostics to $160 From $155 | MT |
Apr. 24 | UBS Adjusts Price Target on Quest Diagnostics to $146 From $139, Maintains Neutral Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-0.24% | 15.28B | |
-14.17% | 85.42B | |
+17.86% | 84.38B | |
+10.92% | 29.39B | |
-8.51% | 17.49B | |
-2.21% | 16.44B | |
-2.34% | 11.71B | |
+0.84% | 12.22B | |
-31.58% | 11.98B | |
+26.71% | 11.64B |
- Stock Market
- Equities
- DGX Stock
- News Quest Diagnostics Incorporated
- Quest Diagnostics Incorporated Provides Consolidated Earnings Guidance for the Fiscal Year 2022